UBS Principal Capital Asia Ltd. recently sold stakes in four Indian companies, namely Concord Biotech Ltd., Five-Star Business Finance Ltd., IIFL Securities Ltd., and Marksans Pharma Ltd. The combined sale was worth Rs 480 crore, according to the bulk deal data on the National Stock Exchange (NSE).
Here’s a breakdown of the transactions:
1. Concord Biotech Ltd.
UBS sold 7.4 lakh shares of Concord, representing a 0.7% stake, at Rs 2,589.86 per share. The total transaction value amounted to Rs 191 crore.
2. Five-Star Business Finance Ltd.
UBS offloaded 15.8 lakh shares of Five-Star Business Finance, representing a 0.54% stake, at Rs 804.74 per share, aggregating to Rs 127 crore.
3. IIFL Securities Ltd.
UBS sold 17.1 lakh shares of IIFL Securities, representing a 0.55% stake, at Rs 309.84 per share, resulting in a total value of Rs 53 crore.
4. Marksans Pharma Ltd.
UBS offloaded 34.01 lakh shares of Marksans Pharma, representing a 0.75% stake, at Rs 317.22 per share, totaling Rs 107 crore.
This significant sale by UBS highlights its reduced holdings in these companies. The bulk deal data suggests that UBS is adjusting its portfolio in the Indian market. The sale has attracted attention due to the substantial value and the companies involved, spanning industries such as pharmaceuticals, finance, and biotech.
Investors will be watching how these companies perform following the sale, especially considering UBS’s strong influence in market activities. The sale may impact stock prices in the short term as traders assess the reasons behind UBS’s decision.
Stay informed with our financial updates, stocks, bonds, commodities. Get global & political insights. Follow us & enable notifications for the latest updates.
